Home About us Contact
|
Home About us Contact | ||
|
|
||
Laboratory Monitoring (laboratory + monitoring)
Selected AbstractsLaboratory monitoring of low-molecular-weight heparin therapyJOURNAL OF THROMBOSIS AND HAEMOSTASIS, Issue 6 2004C. Kearon No abstract is available for this article. [source] Laboratory monitoring of low-molecular-weight heparin therapyJOURNAL OF THROMBOSIS AND HAEMOSTASIS, Issue 6 2004J. N. Fiessinger No abstract is available for this article. [source] Laboratory evaluation of aspirin responsiveness,AMERICAN JOURNAL OF HEMATOLOGY, Issue 5 2010Kristi J. Smock Aspirin is the most commonly used antiplatelet medication. Laboratory monitoring of aspirin response has recently become a topic of interest due to potential impacts on patient management and clinical outcomes. This article summarizes available laboratory testing of aspirin response with focus on technical issues, limitations, and current opinion on the utility of routine patient testing. Am. J. Hematol., 2010. © 2010 Wiley-Liss, Inc. [source] Laboratory monitoring of new anticoagulants,AMERICAN JOURNAL OF HEMATOLOGY, Issue 3 2010Donna D. Castellone Maintaining a balance between bleeding and clotting has always been a challenge in treating coagulation disorders. A perturbation in that balance can be associated with substantial morbidity and mortality. As a result, anticoagulant monitoring is extremely important, and inappropriate testing may lead to complications. There are now a variety of new anticoagulant drugs in clinical use including several direct thrombin inhibitors (DTIs), such as argatroban, bivalirudin, and hirudin, as well as a Factor Xa inhibitor, fondaparinux. There are pitfalls associated with some of the currently used laboratory monitoring tests, and newer alternative laboratory monitoring tests have been investigated (Walenga and Hoppensteadt, Semin Thromb Hemost 2004;30:683,695). In addition, laboratory testing can assist with transitioning patients from DTI to warfarin therapy. Am. J. Hematol. 2010. © 2009 Wiley-Liss, Inc. [source] More on: new antithrombotics: a need for laboratory monitoring.JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Issue 9 2010For or against No abstract is available for this article. [source] New oral antithrombotics: a need for laboratory monitoring.JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Issue 4 2010See also Bounameaux H, Reber G. New oral antithrombotics: a need for laboratory monitoring. Against. This issue, pp 627,30. [source] Review article: Low-molecular-weight heparin as an alternative anticoagulant to unfractionated heparin for routine outpatient haemodialysis treatmentsNEPHROLOGY, Issue 5 2009ANDREW DAVENPORT SUMMARY Unfractionated heparin is currently the most widely used anticoagulant for outpatient haemodialysis. However, unfractionated heparin is a series of molecules, and as such has variable pharmacodynamics. Low-molecular-weight heparins were developed to improve both drug pharmacokinetic and dynamics, so to provide a reliable predictable clinical effect. The low-molecular-weight heparins are potent agents, but have an increased half-life compared with unfractionated heparin, and also require specialist laboratory monitoring. Despite these apparent drawbacks, low-molecular-weight heparins have become the anticoagulants of choice in Western Europe for routine outpatient haemodialysis sessions, due to the reliability of their clinical effect, and ease of administration, coupled with cost reduction. In standard clinical practice laboratory monitoring is not routinely performed, with drug dosing assessed by clinical inspection of the extracorporeal circuit, and the time for fistula needle sites to stop bleeding. [source] A comment on laboratory monitoring of new anticoagulants,AMERICAN JOURNAL OF HEMATOLOGY, Issue 7 2010Bernardo Cortese No abstract is available for this article. [source] FDA drug prescribing warnings: is the black box half empty or half full?,PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 6 2006Anita K. Wagner PharmD Abstract Purpose Black box warnings (BBWs) are the Food and Drug Administration's (FDA) strongest labeling requirements for high-risk medicines. It is unknown how frequently physicians prescribe BBW drugs and whether they do so in compliance with the warnings. The purpose of the present study was to assess the frequency of use of BBW medications in ambulatory care and prescribing compliance with BBW recommendations. Methods This retrospective study used automated claims data of 929,958 enrollees in 10 geographically diverse health plans in the United States to estimate frequency of use in ambulatory care of 216 BBW drugs/drug groups between 1/1/99 and 31/6/01. We assessed dispensing compliance with the BBW requirements for selected drugs. Results During a 30-month period, more than 40% of enrollees received at least one medication that carried a BBW that could potentially apply to them. We found few instances of prescribing during pregnancy of BBW drugs absolutely contra-indicated in pregnancy. There was almost no co-prescribing of contra-indicated drugs with the two QT-interval-prolonging BBW drugs evaluated. Most non-compliance occurred with recommendations for baseline laboratory monitoring (49.6% of all therapy initiations that should have been accompanied by baseline laboratory monitoring were not). Conclusions Many individuals receive drugs considered to carry the potential for serious risk. For some of these drugs, use is largely consistent with their BBW, while for others it is not. Since it will not be possible to avoid certain drug- associated risks, it will be important to develop effective methods to use BBWs and other methods to minimize risks. Copyright © 2005 John Wiley & Sons, Ltd. [source] | ||||||||||